OTCM
FSPKF
Market cap16bUSD
, Last price
Name
Fisher & Paykel Healthcare Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fisher & Paykel Healthcare Corporation Limited, operating with its various subsidiaries, is a global innovator in medical device technology. The company specializes in the design, production, and worldwide distribution of sophisticated products and systems. These solutions primarily cater to acute and chronic respiratory care, support during surgical procedures, and the treatment of obstructive sleep apnea (OSA) in both clinical settings and home environments. Their product lineup includes notable items such as the Airvo 2, a humidified nasal high flow system; Optiflow, designed for nasal high flow therapy; and the F&P 850 System, which offers both non-invasive and invasive ventilation capabilities. For infant care, the company supplies respiratory products used in resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy. Hospital-grade offerings comprise humidification devices, breathing circuits, chambers, diverse masks, nasal cannulas, surgical accessories, and various interfaces. For homecare users, Fisher & Paykel provides masks, CPAP devices, data management software, humidifiers, and complementary accessories. Established in 1934, the company maintains its headquarters in Auckland, New Zealand.
Key people
Non-Executive Independent Chairman of the Board · since 2024
Lyndal York
Chief Financial Officer · since 2019
Andy Niccol
Chief Operating Officer · since 2024
Justin Callahan
Vice President - Sales and Marketing · since 2024
Marcus Driller
Vice President - Corporate · since 2019
Winston Fong
Vice President - Surgical Technologies · since 2017
Nicholas Fourie
Vice President - Information and Communication Technology · since 2017
Jonti Rhodes
Vice President - Supply Chain, Facilities and Sustainability · since 2022
Brian Schultz
Vice President - Quality and Regulatory Affairs · since 2015
Andrew Robert Somervell
Vice President - Products and Technology · since 2016
Lewis Gradon
Chief Executive Officer, Managing Director, Executive Director · since 2016
Desh Edirisuriya
General Manager - New Zealand Operations · since 2024
Nicola Talbot
Vice President - Human Resources · since 2020
Raelene Leonard
General Counsel, Company Secretary · since 2024
Non-Executive Director · since 2016
Cather Simpson
Non-Executive Director · since 2022
Mark Cross
Non-Executive Independent Director · since 2024
Anna Curzon
Non-Executive Independent Director · since 2026
Non-Executive Independent Director · since 2017
Lisa Mcintyre
Non-Executive Independent Director · since 2021
Valuation
Title NZD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||